In the BioHarmony Drug Report Database

"Preview" Icon

Histrelin

Supprelin, Supprelin La, Vantas (histrelin) is a protein pharmaceutical. Histrelin was first approved as Supprelin on 1991-12-24. It is used to treat precocious puberty in the USA. It is known to target gonadotropin-releasing hormone receptor. Vantas’s patent is valid until 2026-06-16 (FDA).

 

Trade Name

 

Supprelin, Supprelin La, Vantas
 

Common Name

 

histrelin
 

ChEMBL ID

 

CHEMBL1201255
 

Indication

 

precocious puberty
 

Drug Class

 

Prehormones or hormone-release stimulating peptides

Image (chem structure or protein)

Histrelin structure rendering